|View printer-friendly version|
Portola Pharmaceuticals to Present at the 2017 Morgan Stanley Global Healthcare Conference
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the
Michele Mantynen Portola Pharmaceuticalsir@portola.com Media Contact: Julie Normart Pure Communicationsjnormart@purecommunications.com